We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.71%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$116M
AUM Growth
+$4.15M
Cap. Flow
-$8.23M
Cap. Flow %
-7.12%
Top 10 Hldgs %
50.71%
Holding
66
New
3
Increased
–
Reduced
29
Closed
2
Avg Time Held Equity + Options
6.2 quarters
Top 10 Avg Time Held Equity + Options
3.1 quarters
Top 20 Avg Time Held Equity + Options
4.5 quarters
Avg Time Held Equity only
6.5 quarters
Top 10 Avg Time Held Equity only
4 quarters
Top 20 Avg Time Held Equity only
5.6 quarters

Top Buys

Rank Stock Value
1
PRQR icon
ProQR Therapeutics
PRQR
+$1.1M
2
KYNB icon
Kyntra Bio
KYNB
+$222K

Top Sells

Rank Stock Value
1
LABU icon
Direxion Daily S&P Biotech Bull 3X ETF
LABU
+$1.37M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$552K
3
NKTR icon
Nektar Therapeutics
NKTR
+$483K
4
JUNO
Juno Therapeutics, Inc.
JUNO
+$456K
5
NBIX icon
Neurocrine Biosciences
NBIX
+$371K

Sector Composition

Rank Sector Weight
1 Healthcare 67.33%
2 Miscellaneous 32.4%
3 Real Estate 0.27%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
REGN icon
26
Regeneron Pharmaceuticals
REGN
$78.5B
$1.53M 1.33%
4,076
-485
-11% -$196K
2014 Q4
12 quarters
BMRN icon
27
BioMarin Pharmaceuticals
BMRN
$10.8B
$1.53M 1.32%
17,118
-2,808
-14% -$244K
2014 Q4
12 quarters
CELG
28
DELISTED
Celgene Corp
CELG
$1.52M 1.31%
14,540
-1,637
-10% -$185K
2014 Q4
12 quarters
LLY icon
29
CALL
Eli Lilly
LLY
$1.05T
$1.27M 1.1%
15,000
– –
2016 Q4
4 quarters
LOXO
30
DELISTED
Loxo Oncology, Inc
LOXO
$1.16M 1.01%
13,800
– –
2017 Q2
2 quarters
ALXN
31
DELISTED
Alexion Pharmaceuticals
ALXN
$1.14M 0.99%
9,558
-1,889
-17% -$230K
2014 Q4
12 quarters
PCRX icon
32
Pacira BioSciences
PCRX
$1.45B
$1.14M 0.99%
25,000
– –
2016 Q3
5 quarters
CLVS
33
DELISTED
Clovis Oncology, Inc.
CLVS
$1.02M 0.88%
15,000
– –
2016 Q4
4 quarters
ADMS
34
DELISTED
Adamas Pharmaceuticals
ADMS
$1.02M 0.88%
30,000
– –
2015 Q4
8 quarters
PRQR icon
35
ProQR Therapeutics
PRQR
$236M
$992K 0.86%
+307,692
New +$1.1M
2017 Q4
0 quarters
KPTI icon
36
Karyopharm Therapeutics
KPTI
$11.6M
$960K 0.83%
6,667
– –
2017 Q2
2 quarters
AXSM icon
37
Axsome Therapeutics
AXSM
$8.7B
$748K 0.65%
133,500
– –
2017 Q1
3 quarters
GILD icon
38
CALL
Gilead Sciences
GILD
$186B
$716K 0.62%
10,000
– –
2017 Q1
3 quarters
PRTK
39
DELISTED
Paratek Pharmaceuticals, Inc.
PRTK
$716K 0.62%
40,000
– –
2015 Q4
8 quarters
CKPT icon
40
DELISTED
Checkpoint Therapeutics
CKPT
$438K 0.38%
11,276
– –
2017 Q2
2 quarters
TSRO
41
DELISTED
TESARO, Inc.
TSRO
$414K 0.36%
5,000
– –
2016 Q4
4 quarters
RARE icon
42
Ultragenyx Pharmaceutical
RARE
$1.5B
$393K 0.34%
8,472
-3,427
-29% -$168K
2016 Q1
7 quarters
MDCO
43
DELISTED
Medicines Co
MDCO
$383K 0.33%
14,000
– –
2015 Q4
8 quarters
BIVV
44
DELISTED
Bioverativ Inc. Common Stock
BIVV
$361K 0.31%
6,689
-4,367
-39% -$239K
2017 Q3
1 quarter
NBIX icon
45
Neurocrine Biosciences
NBIX
$14.4B
$326K 0.28%
4,204
-5,440
-56% -$371K
2016 Q3
5 quarters
SNR
46
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$316K 0.27%
41,850
– –
2016 Q1
7 quarters
AKBA icon
47
Akebia Therapeutics
AKBA
$222M
$312K 0.27%
21,009
– –
2017 Q1
3 quarters
UTHR icon
48
United Therapeutics
UTHR
$23.5B
$303K 0.26%
2,050
-2,058
-50% -$262K
2017 Q3
1 quarter
HRTX icon
49
Heron Therapeutics
HRTX
$78.7M
$287K 0.25%
15,874
– –
2017 Q1
3 quarters
AVXS
50
DELISTED
AveXis, Inc. Common Stock
AVXS
$277K 0.24%
2,500
– –
2016 Q4
4 quarters
1
2
3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q4 2017 Portfolio in Review

As of Q4 2017, Opus Point Partners Management held 66 positions worth $116M, up 3.7% from $111M the previous quarter. Its ten largest holdings account for 51% of the portfolio.

Opus Point Partners Management withdrew a net $8.23M in Q4 2017, closing 2 positions and reducing 29 holdings. Its most notable exit was Direxion Daily S&P Biotech Bull 3X ETF, an estimated $1.37M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 67% of assets, down from 74% a quarter earlier, followed by Miscellaneous and Real Estate.

Against the trend, Opus Point Partners Management opened a new position in ProQR Therapeutics worth $992K.

  • Opus Point Partners Management's largest Q4 2017 buy was ProQR Therapeutics: 307,692 shares worth $992K.
  • Opus Point Partners Management's biggest Q4 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $552K.
  • Opus Point Partners Management fully exited Direxion Daily S&P Biotech Bull 3X ETF in Q4 2017, selling an estimated $1.37M.
  • Opus Point Partners Management's ten largest holdings make up 51% of its $116M portfolio in Q4 2017.
  • Opus Point Partners Management opened 3 new positions and closed 2 in Q4 2017.
  • Opus Point Partners Management's portfolio value rose 3.7% quarter-over-quarter to $116M.

Based on Opus Point Partners Management's 13F filing for Q4 2017, filed 14 Feb 2018.